Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulse Interleukin-2 with Famotidine in AML
NCT01289678Phase 2Terminated
- Sponsor
- Leo W. Jenkins Cancer Center
- Start
- Jul 2006
- Primary completion
- Aug 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in acute myeloid leukemia (AML), sponsored by Leo W. Jenkins Cancer Center. Primary endpoint: Event-free Survival at 3 years. Started Jul 2006; status: terminated.
02
Drugs
aldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01289678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01289678.